Afrezza, world’s only rapid-acting, inhaled insulin for type 1 & type 2 diabetes patients & manufactured by MannKind, ...

Exubera, a rapid-acting insulin in powder form ... are also under investigation. In humans, inhaled regular insulin is more rapidly absorbed than insulin from the subcutaneous injection site.

MESA, AZ (AZFamily) — Inhaled insulin is now considered “standard of care” for diabetics, according to updated guidelines from the American Diabetes Association. Inhaled insulin works faster ...

Cipla to introduce Afrezza, an inhaled insulin for diabetes, offering convenience but not advised for lung-related concerns.

Cipla secures CDSCO approval for Afrezza, its inhaled insulin, marking a breakthrough in diabetes management with innovative ...

India has the 2nd highest burden of diabetes worldwideCDSCO decision follows existing approvals in the U.S.A. and ...

Cipla receives approval to market Afrezza, a rapid-acting insulin inhaler, offering a needle-free solution for diabetes ...

Clinical programs for inhaled insulin have received several setbacks ... Its Technosphere is rapid acting in part because it delivers insulin in monomer form—unlike traditional insulin that ...

Indian regulator Central Drugs Standard Control Organisation (CDSCO) has approved Cipla to exclusively distribute and market ...

This is the first and only non- injectable insulin to be developed for patients of both type 1 and type 2 diabetes mellitus.

About Afrezza Afrezza (insulin human) Inhalation Powder is a rapid-acting inhaled human insulin indicated to improve glycemic control in adults with diabetes mellitus. Limitations of Use ...